<!DOCTYPE html>
<html lang="en">
<head>
	<meta charset="UTF-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	
	<title>Tocophe RX</title>

	<link rel="stylesheet" type="text/css" href="css/style.css">
	<link rel="stylesheet" type="text/css" href="css/slideshow.css">
	<link href='https://fonts.googleapis.com/css?family=Roboto:400,300,100,500,700' rel='stylesheet' type='text/css'>
	<link href="https://maxcdn.bootstrapcdn.com/font-awesome/4.2.0/css/font-awesome.min.css" rel="stylesheet">
	
	<script type="text/javascript" src="http://code.jquery.com/jquery-1.9.1.js"></script>
	<script src="js/jquery.cycle2.min.js"></script>
	<script type="text/javascript" src="js/script.js"></script>
</head>

<body>
<header>
     <a href="index.html" class="logo">Tocophe<span>Rx</span></a>
      <nav class="nav-collapse">
        <ul>
        	<li class="menu-item"><a href="index.html">Home</a></li>
          	<li class="menu-item active"><a href="about-us.html">About Us</a></li>
          	<li class="menu-item"><a href="science.html">Science</a></li>
          	<li class="menu-item"><a href="pipeline.html">Pipeline</a></li>
          	<li class="menu-item"><a href="investors.html">Investors</a></li>
          	<li class="menu-item"><a href="news.html">News</a></li>
          	<li class="menu-item"><a href="contact-us.html">Contact Us</a></li>
        </ul>
      </nav>
</header>
<div class="top-border">
<h4>Innovative Medical solution<br> for Treatment of Infertility</h4>
</div>

<nav class="about-side-nav">
	<ul class="nav">
		<li><a href="#about-us" data-scroll>About Us</a></li>
		<li><a href="#scientific-founders" data-scroll>Founders</a></li>
		<li><a href="#board-of-directors" data-scroll>Board of Directors</a></li>
		<li><a href="#scientific-advisory" data-scroll>Clinical Adisory Board</a></li>
	</ul>
</nav>

<div id="about-us">
	<h3 class="about-us">About Us</h3>
<p>TocopheRx is focused on developing innovative medicines that reduce the stress of infertility treatments
for couples desiring to achieve the family plans.  Our disruptive technology is a small molecule that 
combines the activity of  both hormones used to treat infertility into a single molecule that will be 
delivered in a tablet to treat the infertile partner in a couple, whether it is the woman or the man.</p>
<p>The most significant trend affecting the fertility of both women and men is postponement of child-bearing until careers have been established.  Whether your decision relies on banking oocytes for the right partner, freezing embryos for future implantation, or treatment now to address current fertility problems, an orally active treatment regimen can be less stressful for both partners.</p>
<p>From the inception of TocopheRx, we have been committed to develop fertility treatments that are
extremely safe and highly effective.  Our development program has a strong emphasis on both efficacy 
and safety for patients receiving the treatment. Our goal is to help you reach your family objectives with 
less stress due to drug administration and earlier access to superior treatment options than can be 
achieved currently.</p>
</div>

<div id="scientific-founders">
	<h4 class="about-header">Founders</h4>
		<div class="about-image">
			<img src="images/steve-palmer.jpg" alt="Steve Palmer, PhD, CSO">
		</div>
		<div class="about-people-content">
			<h5>Steve Palmer, PhD, CSO</h5>
			<p>Former Head of Fertility research and early development at EMD Serono. 20 years experience in early drug development in Reproductive Health: J&J: antiprogestins & gonadotropin antagonists; EMDS: JNK inhibitors; gonadotropin analogs; cytokine gonadotropin fusion proteins; GPCR agonists</p>
		</div>

		<div class="about-image">
			<img src="images/selva-nataraja.jpg" alt="Selva Nataraja, PhD">
		</div>
		<div class="about-people-content">
			<h5>Selva Nataraja, PhD, Head of Pharmacology</h5>
				<p>Weizmann Institute Postdoc fellow. 10+ years experience in pharmacology. Selva joined the Serono Reproductive Biology Institute and was instrumental in the development of long acting FSH, innovations for uterine diseases, endometriosis and PCOS.</p>
		</div>

		<div class="about-image">
			<img src="images/henry-yu.jpg" alt="Selva Nataraja, PhD">
		</div>
		<div class="about-people-content">
			<h5>Henry Yu, PhD, Head of Chemistry</h5>
				<p>Scrips Research Institute Postdoc fellow. Experienced medicinal chemist leader in oncology, CNS, Fertility and Immunology. Expertise: small molecule, macrocycle, and antibody-drug conjugate drug discovery. FSHR chemistry leader from Hit, Lead, to preclinical candidates.</p>
		</div>
</div>

<footer class="footer">
  <span class="copyright">
        <h2>Tocophe<span class="rx">Rx</span></h2>
        <h5>Innovative Medical Solution<br> for Treatment of Infertility</h5>
    </span>
  <div id="pattern" class="pattern">
    <div class="col-group">
      <div>
        <i class="fa fa-globe"></i>
        <p>1500 District Ave, Suite 1087</p>
        <p>Burlington, MA, 08102, USA</p>
      </div>
      <div>
        <i class="fa fa-envelope"></i>
        <p>E-Mail:
        <p>info@tocopherx.com</p>
      </div>
      <div>
        <i class="fa fa-phone"></i>
        <p>Phone:
        <p>781-333-4088</p>
      </div>
  </div>
</div>
</footer>

<div class="bottom">
<p>&copy; 2015 TocopheRx</p>
</div>

<script src="js/fastclick.js"></script>
<script src="js/scroll.js"></script>
<script type="text/javascript" src="js/responsive-nav.js"></script>
<script src="js/fixed-responsive-nav.js"></script>	
</body>
</html>